acne mRNA vaccine / Sanofi - LARVOL DELTA

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial primary completion date: Sep 2026 ➔ Jun 2029

Trial primary completion date • Acne Vulgaris

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne (clinicaltrials.gov) - P1/2 | N=260 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Trial primary completion date: Feb 2026 ➔ Aug 2028

Trial primary completion date • Acne Vulgaris

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne (clinicaltrials.gov) - P1/2 | N=120 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Not yet recruiting ➔ Recruiting

Enrollment open • Acne Vulgaris

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne (clinicaltrials.gov) - P1/2 | N=120 | Not yet recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company

New P1/2 trial • Acne Vulgaris

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne (clinicaltrials.gov) - P1/2 | N=260 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | N=386 ➔ 260 | Trial completion date: Mar 2028 ➔ Aug 2028 | Trial primary completion date: Dec 2027 ➔ Feb 2026

Enrollment change • Trial completion date • Trial primary completion date • Acne Vulgaris

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne (clinicaltrials.gov) - P1/2 | N=386 | Recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company | Not yet recruiting ➔ Recruiting

Enrollment open • Acne Vulgaris

Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Adults With Moderate to Severe Acne (clinicaltrials.gov) - P1/2 | N=386 | Not yet recruiting | Sponsor: Sanofi Pasteur, a Sanofi Company

New P1/2 trial • Acne Vulgaris